Evaluation of whole-body cancer screening using 18F-2-deoxy-2- fluoro-D-glucose positron emission tomography: A preliminary report

Annals of Nuclear Medicine

Volumn 22, Issue 5, 2008, Pages 379-385

  Terauchi, Takashi ^a   Murano, Takeshi ^a   Daisaki, Hiromitsu ^a   Kanou, Daisuke ^a   Shoda, Hiroko ^a   Kakinuma, Ryutaro ^a   Hamashima, Chisato ^a   Moriyama, Noriyuki ^a   Kakizoe, Tadao ^a  

^a NATIONAL CANCER CENTER   (Japan)

Author keywords

Cancer screening; Evidence; FDG PET; Screening value; Sensitivity

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ARTICLE; BARIUM ENEMA; BREAST CANCER; CANCER SCREENING; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; ENDOMETRIUM; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; NECK CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE CARCINOMA; SPUTUM CYTODIAGNOSIS; STOMACH CANCER; THYROID CANCER; UTERINE CERVIX; WHOLE BODY PET;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 46649104080     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-008-0130-7     Document Type: Article

References (24)

1. Hamashima H, Sobue T, Muramatsu Y, Saito H, Moriyama N, Kakizoe T. Comparison of observed and expected numbers of detected cancers in the research center for cancer prevention and screening program. Jpn J Clin Oncol 2006;36:301-308.
2. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological application of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-1674.
3. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, et al. Noninvasive grading of muscloskeletal tumors using PET. J Nucl Med 1991;32:1508-1512.
4. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? Eur J Cancer 1995;31A:1924-1927.
5. Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994;8:187-191.
6. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997;79:695-699.
7. 18F]-d-glucose. Cancer 1998;82:2227-2234.
8. Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997.
9. Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Tkahashi W, et al. Application of positron emission tnomography imaging to cancer screening. Br J Cancer 2000;83:1607-1611.
10. Halter G, Storck M, Guhlmann A, Frank J, Grosse S, Liewald F. FDG positron emission tomography in the diagnosis of peripheral focal lesions. Thorac Cardiovasc Surg 2000;48:97-101.
11. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996;26:308-314.
12. Moran JK, Lee HB, Blaufox MD. Optimization of urinary excretion during PET imaging. J Nucl Med 1999;40:1352-1357.
13. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998;39:1016-1020.
14. Stahl A, Ott K, Weber WA, Fink U, Siewert JR, Schwaiger M. Correlation of FDG uptake in gastric carcinomas with endoscopic and histopathological findings (abstract). J Nucl Med 2001;42Suppl:78P.
15. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-924.
16. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002;9:15-18.
17. Torizuka T, Tamaki N, Inokuma T, Nagata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-1817.
18. 18F- fluolrodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100-4104.
19. Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. The detection rate and tumor clinical/pathological stages of whole body FDG-PET cancer screening. Ann Nucl Med 2007;21:65-72.
20. Hisamichi S, Tsuji I, Tsubono Y, Nishino Z. The effectiveness of cancer screening in Japan (in Japanese). Sendai: Tohoku University Press; 2001.
21. Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med 2005;19:167-177.
22. Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma T, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med 2007;21:481-491.
23. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutch SM, et al. Current methods of the U.S. Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20(3S):21-35.
24. Jinnouchi S, Nakajo M, Tateno R, Tanabe H. Analysis of colon cancer detected in cancer screening with FDG-PET: comparing with Feces occult blood test and CEA (in Japanese). Nihon Gan-Kenshinn Shindan Gakkaishi 2007;14:150-155.